Logistic regression model for the aGVHDAI scaled to yield score values that range from 0 to 100
. | Average aGVHDAI model . | . | . | Current interval model . | . | . | Final scaled weight factors . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Factor, scoring level . | Coefficient . | P . | 95% CI . | Coefficient . | P . | 95% CI . | . | ||||
| Liver | |||||||||||
| Total serum bilirubin 2-4 mg/dL | 1.34 | .07 | -0.11, 2.80 | 0.67 | .004 | 0.21, 1.12 | 16 | ||||
| Total serum bilirubin greater than or equal to 5 mg/dL | 1.95 | .053 | -0.02, 3.93 | 1.32 | < .001 | 0.65, 1.99 | 26 | ||||
| Upper gut | |||||||||||
| Oral caloric intake less than 40% of requirements, with poorly controlled anorexia, nausea, and vomiting | 2.64 | .008 | 0.68, 4.61 | 0.41 | .08 | -0.05, 0.87 | 20 | ||||
| Immunosuppressive therapy | |||||||||||
| Any prednisone dose or secondary therapy for GVHD | 1.13 | .21 | -0.62, 2.90 | 0.84 | .02 | 0.12, 1.56 | 17 | ||||
| Performance | |||||||||||
| Unwell, ambulatory, limited in strenuous activity, capable of self-care, and spending more than 50% of waking hours out of bed (scored as CC or DD; see “Patients, materials, and methods”) | 1.81 | .03 | 0.15, 3.48 | 0.80 | .006 | 0.24, 2.48 | 20 | ||||
| Unwell, limited in self-care, and spending more than 50% of time in bed, or worse (scored as EE or FF; see “Patients, materials, and methods”) | 3.11 | .01 | 0.91, 5.31 | 1.65 | < .001 | 0.91, 5.31 | 37 | ||||
. | Average aGVHDAI model . | . | . | Current interval model . | . | . | Final scaled weight factors . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Factor, scoring level . | Coefficient . | P . | 95% CI . | Coefficient . | P . | 95% CI . | . | ||||
| Liver | |||||||||||
| Total serum bilirubin 2-4 mg/dL | 1.34 | .07 | -0.11, 2.80 | 0.67 | .004 | 0.21, 1.12 | 16 | ||||
| Total serum bilirubin greater than or equal to 5 mg/dL | 1.95 | .053 | -0.02, 3.93 | 1.32 | < .001 | 0.65, 1.99 | 26 | ||||
| Upper gut | |||||||||||
| Oral caloric intake less than 40% of requirements, with poorly controlled anorexia, nausea, and vomiting | 2.64 | .008 | 0.68, 4.61 | 0.41 | .08 | -0.05, 0.87 | 20 | ||||
| Immunosuppressive therapy | |||||||||||
| Any prednisone dose or secondary therapy for GVHD | 1.13 | .21 | -0.62, 2.90 | 0.84 | .02 | 0.12, 1.56 | 17 | ||||
| Performance | |||||||||||
| Unwell, ambulatory, limited in strenuous activity, capable of self-care, and spending more than 50% of waking hours out of bed (scored as CC or DD; see “Patients, materials, and methods”) | 1.81 | .03 | 0.15, 3.48 | 0.80 | .006 | 0.24, 2.48 | 20 | ||||
| Unwell, limited in self-care, and spending more than 50% of time in bed, or worse (scored as EE or FF; see “Patients, materials, and methods”) | 3.11 | .01 | 0.91, 5.31 | 1.65 | < .001 | 0.91, 5.31 | 37 | ||||
Final scaled weight factors for the aGVHDAI are averages of the weights from the average and current interval models.
To convert bilirubin from milligrams per deciliter to micromoles per liter, multiply milligrams per deciliter by 17.1.